SFI
IGMS

Susquehanna Fundamental Investments’s IGM Biosciences IGMS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-36,369
Closed -$222K – 1148
2024
Q4 		$222K Buy
+36,369
New +$432K ﹤0.01% 988
2024
Q2 		$110K Sell
16,028
-11,703
-42% -$100K ﹤0.01% 890
2024
Q1 		$268K Buy
+27,731
New +$321K 0.01% 576

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Susquehanna Fundamental Investments's IGMS Position: Q1 2025 in Review

Susquehanna Fundamental Investments sold out of IGM Biosciences (IGMS) in Q1 2025, closing a stake of 36,369 shares — an estimated $222K sold.

Susquehanna Fundamental Investments first reported a position in IGMS in Q1 2024 and held it in 3 quarters. The position peaked at $268K in Q1 2024. 79 funds tracked by Wall St. Rank hold IGMS as of Q1 2025.

  • Susquehanna Fundamental Investments reported no remaining IGM Biosciences position as of Q1 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 36,369 IGM Biosciences shares in Q1 2025, an estimated $222K.
  • Susquehanna Fundamental Investments first reported a position in IGM Biosciences in Q1 2024 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's IGM Biosciences position peaked at $268K in Q1 2024.
  • 79 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2025, filed 14 May 2025.